



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent: HIV-1 gp120 Monoclonal Antibody (F425 B4e8)

Catalog Number: 7626

Lot Number: 080197

Release Category: C

Provided: 100 µg at 2.0 mg/ml in PBS. Purified from tissue culture supernatant by protein G chromatography. The antibody is stable at this concentration. If a less concentrated stock is needed, dilute the material no further than 1 mg/ml.

Description: Purified from tissue culture supernatant by protein G chromatography.

Host Site: EBV-transformed B cell x HMMA2.5 TG/O heteromyeloma.

Titer: Use at 10-20 µg/ml for flow cytometry.

Special Characteristics: Reacts with the base of the V3 loop of gp120; neutralizes primary isolates.

Recommended Storage: Once thawed, maintain at 4°C. DO NOT RE-FREEZE. This antibody is highly sensitive to multiple freeze-thaw cycles.

Contributor: Dr. Marshall Posner and Dr. Lisa Cavacini.

Isotype: IgG₂, kappa.

References: Pantophlet R, Aguilar-Sino RO, Wrin T, Cavacini LA, Burton DR. Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis. *Virology* 2007;**364**:441-53.

Bell CH, Pantophlet R, Schiefner A, Cavacini LA, Stanfield RL, Burton DR, Wilson IA. Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization. *J Mol Biol* 2008;**375**:660-70.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

NOTE:

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 gp120 Monoclonal Antibody (F425 B4e8) from Dr. Marshall Posner and Dr. Lisa Cavacini."

Requests from commercial organizations should be directed to Jodi Hecht, Technology Ventures Office, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, BR2, Boston, MA 02215. Email: jehecht@bidmc.harvard.edu.

Last Updated

March 25, 2014

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.